Featured Articles


Our Picks this year could have turn $1K into over $500K!

Members following our recent picks could have now turned $1,000 into over $500,000 this year alone!!!!

Just check out our recent XTREME gainer plays


TTEG – Turbine Truck Engines, Inc. Takes Ownership of the Detonation Cycle Gas Turbine Engine (DCGT) and Gas-to-Liquid (GTL)

PAISLEY, FL / ACCESSWIRE / November 18, 2014 / Turbine Truck Engines, Inc. (“TTE”) (OTCBB:TTEG, OTCQB:TTEG) announces that all conditions, terms and guarantees of escrow were satisfied allowing Turbine Truck Engines, Inc. (the “Company” or “TTE”) to close, effective November 14, 2014, both the Asset Purchase Agreement and the Technology Sale/Transfer/Assignment for all Intellectual Property (IP) Agreement (the “Agreements”) to obtain ownership, and all rights, title, interest, patents, trademarks, and inventor notes for both the Detonation Cycle Gas Turbine Engine (DCGT) and Gas-to-Liquid (GTL) technologies.


NVIV – Are you catching this, XTREME Breakout!

Ticker: NVIV

Alert Price: $0.60

Last Price: $1.28 (110%)

As we predicted, NVIV broke out of it’s Flag formation and now on an XTREME breakout trading at $1.28 up 110% since our Alert price of $0.60 just a few weeks back. We are seeing lots of upside potential here and news continues to flow our from the company.


NVIV – Showing Brute Force Strength, heading to record levels

Ticker: NVIV

Alert Price: $0.60

Last Price: $1.01 (68%)

Investors who took advantage of our ALERT on NVIV last month are sitting strong with 68% gains, and NVIV shows no signs of slowing down.


NVIV – Soars past our near term target of $1 on more key news

Ticker: NVIV

Alert Price: $0.60

Last Price: $0.90 (50%)

Investors following our social media sites including TWITTER and FACEBOOK have been watching our regular updates on NVIV with key news pushing prices to a high of $1.04 (+73%) and over our near term target of $1. With a minor correction in place, NVIV is setting up for another run to record highs.


InVivo Therapeutics Announces Barnes-Jewish Hospital at Washington University as New Clinical Trial Site for Neuro-Spinal Scaffold

InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Barnes-Jewish Hospital at Washington University Medical Center in St. Louis, MO, is the fourth clinical site in the company’s on-going IDE pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). Barnes-Jewish Hospital is the largest regional trauma center in St. Louis and is one of the largest clinical spine care practices for the United States. Paul Santiago, MD, an Associate Professor of Neurological Surgery and Orthopedic Surgery at the Washington University School of Medicine in St. Louis, will be the study’s Principal Investigator at the Barnes-Jewish Hospital.

Dr. Santiago said, “We look forward to participating in the evaluation of this novel treatment for acute spinal cord injury and hope that it we will be able to advance the treatment of patients with spinal cord injuries.”

Mark Perrin, InVivo Chief Executive Officer, said, “We are pleased that patient enrollment has begun and look forward to bringing more centers of excellence into our current pilot study. With Dr. Santiago and the Barnes-Jewish Hospital, we now have four sites that will be ready to enroll patients once we re-open enrollment. We have received IRB approval from two additional sites, which we will announce in the coming weeks after we complete the final administrative steps of site start-up.”

This is the company’s first clinical study of its investigational degradable polymer Neuro-Spinal Scaffold. The IDE pilot study has been approved by the U.S. Food and Drug Administration (FDA) and is intended to capture preliminary safety and effectiveness data of the Neuro-Spinal Scaffold in five subjects with acute thoracic spinal cord injury. InVivo then expects to conduct a pivotal study to obtain FDA approval to commence commercialization under a Humanitarian Device Exemption (HDE).

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a pioneering biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, ScD., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who then was at Boston Children’s Hospital and now is affiliated with Massachusetts General Hospital. In 2011 the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws.These statements can be identified by words such as “believe,” “anticipate,” “intend,” “estimate,”“will,” “may,” “should,” “expect” and similar expressions, and include statements regarding the Company’s expectations with respect to the safety, feasibility, and clinical effectiveness of its scaffold device, the enrollment of additional patients in the scaffold pilot study following the reopening of enrollment; and its ability to conduct a second pivotal study. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to successfully open additional clinical sites for enrollment; the timing of the Institutional Review Board process; the Company’s ability to obtain FDA approval to commercialize its products; the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, as amended, and its other filings with the SEC, including the Company’s Form 10-Qs and current reports on Form 8-K. The Company does not undertake to update these forward-looking statements.



Investor Relations
Brian Luque, 617-863-5535

Source: InVivo Therapeutics Holdings Corp.



NVIV – On XTREME Alert, significant milestone reached

Ticker: NVIV

Alert Price: $0.60

Last Price: $0.73 (21%)

Members following our social media sites picked up on our XTREME alert – NVIV - which yesterday announced a major milestone in their treatment for spinal cord injuries.

Check out the news here


InVivo Therapeutics Announces First Subject Enrolled in Pilot Spinal Cord Injury Trial

CAMBRIDGE, Mass. (October 15, 2014) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the first subject has been enrolled in the pilot study of its Neuro-Spinal Scaffold for the treatment of complete traumatic spinal cord injury (SCI) at the Barrow Neurological Institute at St. Joseph’s Hospital and Medical Center in Phoenix, AZ. The objective of the pilot study is to evaluate the safety and feasibility of the Neuro-Spinal Scaffold as well as to gather preliminary evidence of effectiveness.

Dr. Nicholas Theodore, Chief of Spinal Surgery, Barrow Neurosurgical Institute and Medical Director of the Neurological Trauma Program, is a Principal Investigator in this study and implanted the first-ever Neuro-Spinal Scaffold into an acute spinal cord injury patient. “I am excited about my participation in this important clinical trial,” Dr. Theodore said. “The surgery and Neuro-Spinal Scaffold implantation went smoothly and the patient is doing well at this time. I look forward to continuing to help evaluate this approach in patients with these devastating injuries.”

Mark Perrin, InVivo’s CEO, said: “This is a major milestone not only for the company, but also for the field of traumatic SCI. InVivo is striving to provide benefit to the SCI patient population with such a huge unmet medical need, and this clinical trial is the first step. We look forward to communicating our progress and moving forward. InVivo will be making announcements after each site has joined the study, after each subject is enrolled, and once enrollment is re-opened for subsequent patients. We consider patient privacy of the utmost importance and will thus communicate any interim information according to industry standards. With the exception of dramatically positive or negative results, we will look to communicate progress at appropriate medical or scientific forums.”

As previously stated and per FDA requirements, the company will follow the first enrolled subject for three months before re-opening enrollment.

For more information, please visit our registration site:
- See more at: